# OnCo record kras-g12c-colorectal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/kras-g12c-colorectal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "kras-g12c-colorectal" ;
  schema:name "KRAS G12C-mutant colorectal cancer"@en ;
  schema:alternateName "KRAS G12C colorectal cancer"@en, "G12C-mutant bowel cancer"@en, "RAS-mutant colorectal cancer (G12C subset)"@en ;
  schema:description "KRAS G12C bowel cancer carries a mutation that was undruggable for forty years. The first KRAS drugs work only weakly on their own in the bowel, because the tumour switches EGFR back on, so they are given with an anti-EGFR antibody: sotorasib with panitumumab and adagrasib with cetuximab are both approved after chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/kras-g12c-colorectal/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/KRAS> ;
  schema:citation <https://en.wikipedia.org/wiki/KRAS>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/glecirasib/>, <https://onco.cc/drugs/daraxonrasib/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/colorectal-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/sidedness/> ;
  onco:trials <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/trials/nct03785249/>, <https://onco.cc/trials/nct06252649/>, <https://onco.cc/trials/nct04793958/>, <https://onco.cc/trials/sunlight/>, <https://onco.cc/trials/fresco-2/>, <https://onco.cc/trials/nct05194995/>, <https://onco.cc/trials/nct07259590/> ;
  onco:pipeline <https://onco.cc/trials/nct06252649/>, <https://onco.cc/trials/nct04793958/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/glecirasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/trials/nct05194995/>, <https://onco.cc/trials/nct07259590/>, <https://onco.cc/drugs/vs-7375/> ;
  onco:standardOfCare <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/trials/nct03785249/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/trials/nct06252649/>, <https://onco.cc/trials/sunlight/>, <https://onco.cc/trials/fresco-2/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/regorafenib/> .